Hummingbird is focused on applying advances in systems biology to rapidly develop antibodies into successful cancer therapeutics. The company will use the funds raised to advance its lead programs towards the clinic with plans to submit the first IND in 2018. The programs in question; HMBD-001 targeting a novel mechanism on HER3, and HMBD-002 targeting a novel epitope on VISTA, have already shown great promise in early animal studies.